> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Determination on Rozlytrek Corrected
- URL: https://www.fdaweb.com/regulatory-review-determination-on-rozlytrek-corrected/
- Published: 2023-11-16T12:00:00.000Z
- Updated: 2026-09-14T14:16:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5155804

*Federal Register* notice: FDA is correcting a notice that appeared in the 7/8/2022 *Federal Register* announcing an agency determination of the regulatory review period for Genentech’s Rozlytrek tablets (entrectinib), indicated for treating certain adult patients with metastatic non-small cell lung cancer, among other indications. The earlier notice was published with an incorrect dosage form, and this notice corrects that. To view the notice, click [here](https://public-inspection.federalregister.gov/2023-25489.pdf?ref=fdaweb.com).